KRAS and non-small cell lung carcinoma: Our data illustrated that ALK-mutated NSCLC patients had a lower population of activated immune markers, such as CD3, CD8, Granzyme B, and CD20, and a higher expression of immunosuppressive markers, such as TIM3, than KRAS-mutated NSCLC patients.